Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07665892 Dihydroergotamine Mesylate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665892 clinical trial report covering Dihydroergotamine Mesylate, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07666022 MF1 Young onset Parkinson disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07666022 clinical trial report covering MF1, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07665879 Eloralintide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665879 clinical trial report covering Eloralintide, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664735 OPB-201 Recurrent ovarian cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664735 clinical trial report covering OPB-201, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
![NCT07664397 [89Zr]DFO-YS5 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook](https://synapse-static.patsnap.com/strapi-static/Blog_cover_B_112_156d4a2e9d.jpg)
Latest Hotspot
8 min read
NCT07664397 [89Zr]DFO-YS5 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664397 clinical trial report covering [89Zr]DFO-YS5, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664176 Nivolumab Ependymoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664176 clinical trial report covering Nivolumab, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664631 Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamp Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664631 clinical trial report covering Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamp, Phase 1, endpoints, sponsor, g
Latest Hotspot
8 min read
NCT07669012 Dexmedetomidine Hydrochloride Sedation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07669012 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 1, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07667621 Rimegepant Sulfate Migraine With Aura Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667621 clinical trial report covering Rimegepant Sulfate, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07668557 Fludarabine Phosphate Refractory acute myeloid leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668557 clinical trial report covering Fludarabine Phosphate, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07668999 ZYG24004 Tinea Pedis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668999 clinical trial report covering ZYG24004, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262404 QM103 BCMA Positive Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262404 clinical trial report covering QM103, Phase 1, endpoints, sponsor, geography, readout timing and development white space.